Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CLPP | Q16740 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11838459 | 0.92 | MEN1 (0.65) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL11833023 | 0.90 | KMT2A (0.66) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| Hydrochloric Acid SCHEMBL11836996 | 0.89 | MEN1 (0.64) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL7638824 | 0.86 | MEN1 (1.00) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL16210859 | 0.85 | KMT2A (0.60) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL17792388 | 0.85 | MEN1 (0.60) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL6609886 | 0.84 | MEN1 (0.73) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL15131972 | 0.82 | KMT2A (0.57) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL16400998 | 0.82 | C5AR1 (0.59) | KMT2AMEN1NPC1RAB9AC5AR1 | |
| SCHEMBL12301081 | 0.82 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-05-06 | — | — | US | disclosed |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3022205-B1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| EP-3022205-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009930-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-01-22 | — | — | WO | disclosed |
| EP-0997462-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | NIPPON KAYAKU KK (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-6294547-B1 | Naphthyridine deratives or salts thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-0997462-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES OR SALTS THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | KMT2A 1442/4885MEN1 3763/4885NPC1 3604/4885 |
| US-11851427-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | KMT2A 1299/4885MEN1 3414/4885NPC1 3586/4885 |
| US-10899756-B2 | Phosphodiesterase inhibitors and uses thereof | PDE5A, PDE2A, PDE3A | KMT2A 1299/4885MEN1 3414/4885NPC1 3586/4885 |
| US-20210130349-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | KMT2A 1442/4885MEN1 3763/4885NPC1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.